Cited by 686Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

André, Thierry, de Gramont, Armand, Vernerey, Dewi, Chibaudel, Benoist, Bonnetain, Franck, Tijeras-Raballand, Annemilaï, Scriva, Aurelie, Hickish, Tamas, Tabernero, Josep, Van Laethem, Jean Luc, Banzi, Maria, Maartense, Eduard, Shmueli, Einat, Carlsson, Goran U., Scheithauer, Werner, Papamichael, Demetris, Möehler, Marcus, Landolfi, Stefania, Demetter, Pieter, Colote, Soudhir, Tournigand, Christophe, Louvet, Christophe, Duval, Alex, Fléjou, Jean-François, de Gramont, Aimery·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2015.63.4238

Open this paper in CoChat — free account

Abstract

Purpose: The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods: Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. Results: After a median follow-up of 9.5 years, 10-year OS rates in the bolus/infusional fluorouracil plus leucovorin (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX4) arms were 67.1% versus 71.7% (hazard ratio [HR], 0.85; P = .043) in the whole population, 79.5% versus 78.4% for stage II (HR, 1.00; P = .980), and 59.0% versus 67.1% for stage III (HR, 0.80; P = .016) disease. Ninety-five patients (9.4%) had MMR-deficient (dMMR) tumors, and 94 (10.4%) had BRAF mutation. BRAF mutation was not prognostic for OS (P = .965), but dMMR was an independent prognostic factor (HR, 2.02; 95% CI, 1.15 to 3.55; P = .014). HRs for DFS and OS benefit in the FOLFOX4 arm were 0.48 (95% CI, 0.20 to 1.12) and 0.41 (95% CI, 0.16 to 1.07), respectively, in patients with stage II to III dMMR and 0.50 (95% CI, 0.25 to 1.00) and 0.66 (95% CI, 0.31 to 1.42), respectively, in those with BRAF mutation. Conclusion: The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the disease severity, was confirmed at 10 years in patients with stage II to III colon cancer. These updated results support the use of FOLFOX in patients with stage III disease, including those with dMMR or BRAF mutation.

Integrity signals

Registry

Crossref · 10.1200/jco.2015.63.4238

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
Self-citation
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
André, T., Boni, C., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Bonetti, A. V., Clingan, P. R., Bridgewater, J. A., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,276
Self-citation
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J. A., McAllister, P. K., Cutsem, E. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,438
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A. M. R., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt354 · Cited by 1,436
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,178
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07
Kuebler, J. P., Wieand, H. S., O’Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P. N., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,055

Flagged first, then by citations

Show all 32 references

Sorted by citations

Items 601–686 of 686

Prognostische und prädiktive Biomarker beim kolorektalen Karzinom
Stintzing, S., & Jelas, I. (2022) · Trillium Diagnostik · doi:10.47184/td.2022.03.03
Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)
Kemeny, M. M., Zhao, F., Forastiere, A. A., Catalano, P. J., Hamilton, S. R., Miedema, B. W., Dawson, N. A., Weiner, L. M., Smith, B. D., Mason, B. A., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12705-8
Mutations in Classical Signaling Pathways and Their Functional Impact in Microsatellite Instability High Colorectal Cancer
Shi, S., Gong, Y., Li, X., Ding, Y., Song, G., Liu, H., & Zhang, Z. (2023) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2022.0118
Implications of the mismatch repair-deficient status for the management of colorectal cancers
Wei, Q., & Shen, L. (2017) · Oncology and Translational Medicine · doi:10.1007/s10330-016-0188-8
The lncRNA TRG-AS1 promotes the growth of colorectal cancer cells through the regulation of P2RY10/GNA13Preprint
Zhuang, L., Luo, B., Deng, L., Zhang, Q., Li, Y., Sun, D., Zhang, H., & Zhang, Q. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.04.547664
LncRNA-ABALON potentiates mitophagy and 5-FU resistance in colorectal cancer via PINK1/Parkin pathwayPreprint
Liu, H., Huang, Y., Zhao, C., Wang, G., & Wang, X. (2023) · Research Square · doi:10.21203/rs.3.rs-3224245/v1
Pilot radiogenomic evaluation of colorectal cancer - Are there preoperative radiological features of the dMMR phenotype?
Lloyd, A., Ryan, É. J., Clifford, S. M., MacDermott, R., Stakelum, Á., Climent, M., Sheahan, K. D., Kennelly, R. P., Hanly, A. M., Martin, S., et al. (2023) · The Royal College of Radiologists Open · doi:10.1016/j.rcro.2023.100003
The effects of chemoradiotherapy in IIA（T3N0M0）rectosigmoid junction cancer : a population-based studyPreprint
zhu, S. R., Tu, J., Pei, W., Zheng, Z., Bi, J., & Feng, Q. (2023) · Research Square · doi:10.21203/rs.3.rs-3490980/v1
Predicting Recurrence and Metastasis in Stage III Colorectal Cancer After Laparoscopic Surgery and Laparotomy
Falsafi, A., Zadeh, A. M. B., Tadayon, S. M. K., & Hosseini, S. V. (2023) · Frontiers in Health Informatics · doi:10.30699/fhi.v12i0.525
Adjuvant treatment for colorectal cancer
Liberko, M., & Soumarová, R. (2023) · Onkologie · doi:10.36290/xon.2023.066
Endoplasmic reticulum stress signaling actively contributes to therapy resistance in colorectal cancerPreprint
Sasaki, D., Sato, N., Wilhelm, D., Fischer, J. C., Gissibl, J., Nakatsuji, M., Haller, D., Ishihara, H., & Janssen, K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.07.574523
Stage II Colon Cancer: Towards an Individualized Treatment Approach
Dosunmu, G. T., & Liao, C. (2023) · Difficult decisions in surgery: an evidence-based approach · doi:10.1007/978-3-031-42303-1_17
Recent Advancement in Nanotechnological Approaches for Increasing the Effectiveness of Herbal Drugs in the Treatment of Colorectal Cancer
Archana, & Deshmukh, R. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947279599231208095726
Kolonkarzinom
Mehdorn, M., Kobitzsch, B., Rabe, S. M., Gockel, I., & Stelzner, S. (2024) · coloproctology · doi:10.1007/s00053-024-00777-x
Additional file 2 of The platelet to lymphocyte ratio is a potential inflammatory marker predicting the effects of adjuvant chemotherapy in patients with stage II colorectal cancer
Fu, Y., Chen, X., Song, Y., Huang, X., Chen, Q., Lv, X., Gao, P., & Wang, Z. (2021) · Figshare · doi:10.6084/m9.figshare.14936205
Additional file 2 of Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis
Chen, Y., Yu, Z., Lv, M., Cai, Z., Zou, Y., Lan, P., Wu, X., & Gao, F. (2021) · Figshare · doi:10.6084/m9.figshare.16909933
Additional file 1 of The platelet to lymphocyte ratio is a potential inflammatory marker predicting the effects of adjuvant chemotherapy in patients with stage II colorectal cancer
Fu, Y., Chen, X., Song, Y., Huang, X., Chen, Q., Lv, X., Gao, P., & Wang, Z. (2021) · Figshare · doi:10.6084/m9.figshare.14936199
Additional file 1 of TRIM69: a marker of metastasis and potential sensitizer to 5-Fluorouracil and PD-1 blockers in colon adenocarcinoma
Chi, X.-J., Song, Y.-B., Liu, D.-H., Wei, L.-Q., Zhao, A., An, X., Feng, Z.-Z., Lan, X.-H., Lv, Y.-M., Li, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24070274
Influence of High-Risk Pathological Factors and their Interaction on the Survival Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer: A Retrospective Study
Zhao, K., Li, H., Pang, W., Zhao, X., Zhang, B., Fen, Z., Jin, L., Xue, J., Chu, T., Yan, S., et al. (2024) · Journal of Cancer · doi:10.7150/jca.95769
Prognostic relevance of preoperative CA 19-9 values in stage III rectal adenocarcinoma: retrospective analysis and clinical implications
Hodžić, E., Pušina, S., Mulabdić, A., Salibasic, M., Halilović, E., & Kadric, M. (2024) · Medicinski Glasnik · doi:10.17392/1701-21-02
An SNP Marker Predicts Colorectal Cancer Outcomes with 5-Fluorouracil-Based Adjuvant Chemotherapy Post-Resection
Chien, H., Chu, Y., Hsu, Y.-P., Yeh, C., Lai, M., Chang, M., Lim, S., Chen, C.-W., & Lin, W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126642
Immunotherapeutic strategies for the treatment of colorectal cancer
Parisi, A., Arrichiello, G., Salati, M., & Petrillo, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13376-3.00003-4
Modelling oxaliplatin resistance in colorectal cancer reveals a SERPINE1 -based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtypePreprint
Wong, S. Q. R., Das, M., Shirgaonkar, N., Tenzin, K., Chua, H., Chee, L. X., Ahpa, S. Y., Murugiah, A. A., Chua, W. Y., Theardy, M. S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.17.628817
Qu-Shi-Jie-Du decoction for prevention of recurrence and metastasis in high-risk stage II/III colon cancer: Study protocol for a double-blind, randomized, placebo-controlled trialPreprint
Chen, Y., He, Z., Zhao, W.-J., He, Y., Liu, Y., Zhu, Y.-J., Yu, Y., Xiao, Z., Chang, X., Liu, Z., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-5908874/v1
Combined preoperative and post-adjuvant-chemotherapy carcinoembryonic antigen levels are prognostic for early recurrence and survival in stage III colon cancer
Akkuş, E., Karaoğlan, B. B., Akçadağ, B., Bahçekapılı, B., Akyol, C., & Utkan, G. (2025) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2025.116256
Treatment Adherence to Adjuvant Chemotherapy According to the New Standard 3-month CAPOX Regimen in High-risk Stage II and Stage III Colon Cancer: A Population-based Evaluation in The Netherlands
van den Berg, K., van Erning, F. N., Burger, J. W. A., van Hellemond, I. E. G., Roodhart, J. M. L., Koopman, M., Rutten, H. J. T., & Creemers, G. (2025) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2025.02.006 · Cited by 2
Hepatic Arterial Infusion Therapy: Considerations for Concurrent Systemic Therapy
Raphael, M. J., Harrold, E. C., Cercek, A., & Krauss, J. C. (2025) · Springer eBooks · doi:10.1007/978-3-031-74935-3_12
Advances in the management of lung & gastro-intestinal cancers: clinical studies review from ASCO 2022/2023 annual meetings
Elmarrachi, H., Andrif, M., & Ismaili, N. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100974
Molecular Targets in Metastatic Colorectal Cancer: A Review
Colombo, A., & Porretto, C. M. (2025) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0045-1812018
Endoplasmic Reticulum Stress and Emerging Therapeutic Targets in Cancer
Yeap, J. W., & Tan, M. L. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_271
Immunotherapy for Colorectal Cancer
Zhang, C., COX, R. A., & Chakrabarti, S. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_220
Chimiothérapie adjuvante du cancer du côlon
Lourenço, N., & Goèré, D. (2020) · Elsevier eBooks · doi:10.1016/b978-2-294-77454-6.00011-8
KRAS, APC, and TP53 mutations define opposing immune archetypes in stage III colorectal cancerPreprint
Chaiboonchoe, A., Tanjak, P., Suwatthanarak, T., Thanormjit, K., Acharayothin, O., Vorasan, N., Sakamula, R., Likhityungyuen, T., Suktitipat, B., Korphaisarn, K., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7903094/v1
Additional file 2 of TRIM69: a marker of metastasis and potential sensitizer to 5-Fluorouracil and PD-1 blockers in colon adenocarcinoma
Chi, X.-J., Song, Y., Liu, D., Wei, L., Zhao, A.-R., An, X., Feng, Z.-Z., Lan, X.-H., Lv, Y.-M., Li, H.-J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24070277
Additional file 1 of Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan
Yu, Y.-L., Tseng, W.-K., Liao, C.-K., Yeh, C.-Y., Chen, H.-H., Liu, Y.-H., Liaw, Y.-W., & Fan, C.-W. (2023) · Figshare · doi:10.6084/m9.figshare.24196792
Additional file 2 of Vasorin (VASN) overexpression promotes pulmonary metastasis and resistance to adjuvant chemotherapy in patients with locally advanced rectal cancer
Kang, D., Huang, S., Liao, Y., Mi, S., Zhou, J., Feng, Y., Huang, R., Lu, Z.-H., Pan, Z. Z., Ma, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26758222
Additional file 1 of Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Figshare · doi:10.6084/m9.figshare.20330034
Additional file 3 of The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
Liao, L., Tang, J., Hong, Z., Jiang, W., Li, Y., Kong, L., Han, K., Hou, Z., Zhang, C., Zhou, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26675783
FIGURE 13 in A new microphthalmic stygobitic Graptodytes Seidlitz from Morocco, with a molecular phylogeny of the genus (Coleoptera, Dytiscidae)
Ribera, I., & Faille, A. (2010) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.198606
Additional file 1 of Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study
Li, K., Zhao, F., Guo, Y., Wu, Q., Luo, S., Zhang, J., Li, H., Hu, S., Wu, B., Lin, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26612798
Additional file 1 of The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
Liao, L., Tang, J., Hong, Z., Jiang, W., Li, Y., Kong, L., Han, K., Hou, Z., Zhang, C., Zhou, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25132137
Additional file 1 of Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis
Song, Y., Mao, Q., Zhou, M., Liu, C.-J., Kong, L., & Hu, T. (2024) · Figshare · doi:10.6084/m9.figshare.25132128
Additional file 3 of Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis
Chen, Y.-F., Yu, Z., Lv, M., Cai, Z.-R., Zou, Y.-F., Lan, P., Wu, X.-J., & Gao, F. (2021) · Figshare · doi:10.6084/m9.figshare.16909936
Additional file 2 of The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
Liao, L., Tang, J., Hong, Z., Jiang, W., Li, Y., Kong, L., Han, K., Hou, Z., Zhang, C., Zhou, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25132200
Additional file 1 of Vasorin (VASN) overexpression promotes pulmonary metastasis and resistance to adjuvant chemotherapy in patients with locally advanced rectal cancer
Kang, D., Huang, S., Liao, Y., Mi, S., Zhou, J., Feng, Y., Huang, R., Lu, Z.-H., Pan, Z. Z., Ma, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26758219
Additional file 1 of Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis
Chen, Y.-F., Yu, Z., Lv, M., Cai, Z.-R., Zou, Y.-F., Lan, P., Wu, X.-J., & Gao, F. (2021) · Figshare · doi:10.6084/m9.figshare.16909930
Additional file 1 of Interconnectivity between molecular subtypes and tumor stage in colorectal cancer
Coebergh van den Braak, R. R. J., ten Hoorn, S., Sieuwerts, A. M., Tuynman, J. B., Smid, M., Wilting, S. M., Martens, J. W. M., Punt, C. J. A., Foekens, J. A., Medema, J. P., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12922094
Additional file 2 of Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study
Li, K., Zhao, F., Guo, Y., Wu, Q., Luo, S., Zhang, J., Li, H., Hu, S., Wu, B., Lin, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26612801
Province-Wide Implementation of Pre-Therapeutic DPYD Genotyping to Prevent Severe Fluoropyrimidine Toxicity in British Columbia
Osei, D., Mensah, K. A., & Boateng, K. (2024) · Specialty journal of Pharmacognosy Phytochemistry and Biotechnology · doi:10.51847/41v7f2srfy
Adult Pan-Colonic Intussusception Secondary to Poorly Differentiated Cecal Adenocarcinoma: A Rare Presentation of Stage IIA Colon Cancer
Cushman, C. J., Coffin, M. L., Archer, T., Nazim, M., & Elfedaly, M. (2026) · Cureus · doi:10.7759/cureus.101382
Development and validation of a multimodal model based on histopathological and computed tomography imaging for predicting survival outcomes in stage III colorectal cancer
Li, D., Zhao, Z., Wei, G., Qiu, W., Lin, Z., He, J., Li, B., Wang, J., Zheng, L., Feng, F., et al. (2026) · Open Research (University of Surrey) · doi:10.1002/viw.20250131
Risk stratification by minimal residual disease detection and ctDNA dynamics from personalised assays in stage II-III colorectal cancer in a UK multi-centre prospective study (TRACC Part B)Preprint
Slater, S., Sng, C. C. T., Anandappa, G., Chen, H.-C., Begum, R., Sharma, S., Laliotis, G., Renner, D., Lazaro-Alcausi, R., Rana, T., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8574150/v1
Minimum 18-week chemotherapy improves survival in locally advanced rectal cancer after neoadjuvant radiotherapy: a post hoc analysis of the STELLAR trial
Xu, T., Ma, H., Zhang, W., Yang, Y., Xiao, W., Li, N., Li, H., Gao, Y., Liu, S., Wei, L., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04731-0
Integrative approaches to colorectal cancer
Lee, R. W., Bahri, N., Kim, E., Blarigan, E. L. V., Wood, K. C., & Atreya, C. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30194-0.00027-8
Microbiota-driven immunometabolic regulation in colorectal cancer: Mechanisms and therapeutic opportunities
Luan, W.-Y., Zhang, S.-P., Xu, K.-Z., Shang, Y.-H., Hu, W., Sun, H., & Miao, Y. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v18.i3.115722
Qu-Shi-Jie-Du Decoction for Prevention of Recurrence and Metastasis in High-Risk Stage II/III Colon Cancer: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial
Chen, Y., He, Z., Zhao, W.-J., He, Y., Liu, Y., Zhu, Y.-J., Yu, Y., Xiao, Z., Chang, X., Liu, Z., et al. (2026) · Integrative Cancer Therapies · doi:10.1177/15347354251396002
CT-based radiomics signature for optimizing adjuvant chemotherapy decisions in stage II colorectal cancer with proficient mismatch repair
Tang, H., Xie, Y., Li, Q., Zhou, Y., Zhao, X., Zheng, Y., Liu, L., Li, Y. Q., Huang, Y., & Mao, Y. (2026) · Abdominal Radiology · doi:10.1007/s00261-026-05456-7
Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma
Marqués, A., Henriques, J., Vernerey, D., Parc, Y. R., Lefèvre, J. H., Voron, T., Cohen, R., André, T., & Samaille, T. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01035
Self-citation
Peripheral Nerve Surgery and Chemotherapy: A Review, Index, and Decision Tree for Nerve Surgeons Considering Neurotization After Oncological Nerve Injuries
ElNemer, W. G., Foster, C. H., Ali, M., Khalifeh, J. M., Höke, A., Lubelski, D., Belzberg, A. J., & TUFFAHA, S. H. (2026) · Neurosurgery Open · doi:10.1227/neuprac.0000000000000206
Implication de la sortiline dans la résistance des cellules cancéreuses au 5-Fluorouracile. Cas du cancer colorectal
Blondy, S. (2019) · theses.fr (ABES) · doi:10.70675/21aba473z09b8z4c23z941fz3b6d04b8b762
Caractérisation phénotypique et clinique des cancers colorectaux métastatiques avec instabilité des microsatellites
Cohen, R. (2018) · doi:10.70675/0879b452z2c14z430eza141z769f71c48c1e
Prognostic and clinicopathologic significance of BRAF mutation in colon cancer by MSI status and stage: A large cohort analysis
Sayed, M. E., Youssef, S., Shealy, M. W., & Harati, M. E. (2026) · Surgical Oncology · doi:10.1016/j.suronc.2026.102419
Probabilistic graphical models for statistical genetics and survival analysis. Application to the Lynch syndrome
Lefebvre, A. (2022) · doi:10.70675/0f8b7ef5z80f0z4aa6zbaeez8b7d84fba489
Le rôle de deux alarmines extracellulaires, HMGB1 et l’ATP, dans le cadre du cancer colorectal
Dillard, C. (2021) · theses.fr (ABES) · doi:10.70675/51029938z640az4398za0f8z6a69fb660b30
Instabilité des microsatellites et cancer : mise à profit du séquençage de nouvelle génération pour l’identification de ce phénotype tumoral et l’analyse des mécanismes de résistance à l’immunothérapie
Ratovomanana, T. (2021) · theses.fr (ABES) · doi:10.70675/440c7edcz62d4z4a0fzac48z88fe67ce18bb
Characterizing Resistance Mechanisms to Immune Checkpoint Blockades in Mismatch Repair-Deficient Tumors
Nebot-Bral, L. (2021) · theses.fr (ABES) · doi:10.70675/e1797b79z28d4z4e65zbd29zdc771b604d21
Hétérogénéité moléculaire du cancer du côlon avec impact pronostique dans le cancer du côlon de stade III et impact prédictif de l'efficacité de l'immunothérapie dans le cancer du côlon métastatique MSI
Gallois, C. (2024) · theses.fr (ABES) · doi:10.70675/5e166e21ze63az4f38z8d1cz2d21ba18c7f0
Efficacy of Renin-Angiotensin System Inhibitors in Long-Term Oncologic Outcomes of Patients With Stage II/III Colon Cancer and Hypertension: A Target Trial Emulation
Chen, K., Xu, D., Zhang, Z. G., Liang, F. Y., He, G. D., Xu, J., & Feng, Q. Y. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01296 · Cited by 1
Relationship between ileocolic arterial stump length and lymph node yield – a retrospective study using machine learning
Zayas-Borquez, R., Arizaga-Ramírez, M. S., Canto-Losa, J., Gándara-Lois, A. C., Salgado‐Nesme, N., Alvarez-Bautista, F. E., & Santes, Ó. (2026) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-026-04048-9
ctDNA-guided adjuvant therapy in stage II colon cancer: a step forward, but not the final word
Tarazona, N., & Parikh, A. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.06.002
Comparative Effectiveness of Oral Fluoropyrimidines Versus FOLFOX as Adjuvant Therapy for Stage III Colon Cancer: A Retrospective Cohort Study Using Overlap‐Weighted Restricted Mean Survival Time Analysis
Huang, S., Hsu, C.-W., Wu, C., & Chen, Y. S. (2026) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70427
Effect of adjuvant chemotherapy on survival in stage IIA colon cancer with partial bowel obstruction after propensity score matching
Yang, I. J., Kim, D. H., Lee, K. H., & Kim, J. (2026) · Discover Oncology · doi:10.1007/s12672-026-05580-2
Epigenetic aging during adjuvant chemotherapy for colon cancer and modification by a resistance training intervention
Binder, A. M., Weltzien, E. K., Feliciano, E. M. C., Brown, J. C., Lee, C., Ross, M. C., Campbell, K. L., Castillo, A., Perez, A. P., Meyerhardt, J. A., et al. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag226
Artificial intelligence applications in oxaliplatin-based chemotherapy for colon cancer: advancing prognosis, toxicity prediction, and dose personalization
Jammoul, D., Ajibuwa, F., Jammoul, M., Schlosser‐Hupf, S., Müller, M., & El‐Najjar, N. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1784272
Exploring disparities in adherence to colorectal cancer clinical practice guidelines and associated survival outcomes: a systematic review and meta-analysis
Gunasekaran, G. H., Ibrahim, B., Saleem, F., & Shabaruddin, F. H. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-11134-7
Risk of Relapse and Efficacy of Adjuvant Chemotherapy in Localized Appendiceal Adenocarcinoma
Khoury, S. E., Fanaeian, M. M., Yousef, M., Yousef, A., Chowdhury, S., Peterson, J., Haque, E., Hornstein, N. J., Taggart, M. W., Foo, W. C., et al. (2026) · JAMA Surgery · doi:10.1001/jamasurg.2026.4000
Postoperative circulating tumor DNA in stage II colon cancer: biological rationale, clinical evidence, and unresolved challenges
Yang, E., Wang, X., Zhang, J., Zhao, D., Yang, Z., Li, X., He, G., Guo, T., Wang, R., & Yuan, B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908802
Glucose-containing carriers in cancer therapy (GLUCOSE-ONC): A multistream critical review and quantitative exposure framework
Kashiwagi, S., Watanabe, C., Asaka, Y., Henmi, S., Matsuda, H., Ding, H., Kikukawa, Y., Gose, A., Nishimoto, M., Kochi, A., et al. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101370
Clinical impact of prospective circulating tumour DNA testing for minimal residual disease in colorectal cancer: the INTERCEPT programme experience
Maddalena, G., Aziz, K. E., Sun, R., Newhook, T. E., Alfaro, K. D., Bowling, A., Gil, D. N., Behman, R. S., Yousef, M., You, Y. N., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-339167
Postoperative chemotherapy reintroduction in good responders after colorectal liver metastases resection: A French randomized phase III trial - IRIMAD
Labiad, C., Brouquet, A., Bachet, J.-B., Abdalla, S., Lefèvre, J. H., Vicaut, É., & Benoist, S. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.09.014
Kolorektales Karzinom
Dapper, H., Rödel, C., & Fokas, E. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-41395-7.60007-8
Structured physical activity in high-risk stage II and stage III colon cancer: tertiary prevention of colorectal cancer recurrence or primary prevention in a population at high risk of secondary cancers?
Moretto, R., Conca, V., Blondeaux, E., & Cremolini, C. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108601
S3-Leitlinie Kolorektales Karzinom
Pox, C. P., Reichermeier, S., Aretz, S., Graeven, U., Hüneburg, R., Hüppe, D., Koch, C., Köhne, C.-H., Kolligs, F. T., Ludwig, L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2853-0320
Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
Chalabi, M., van den Dungen, L. D. W., de Gooyer, P., Balduzzi, S., Aalbers, A. G. J., Kerver, E. D., Grootscholten, C., Dokter, S., Bloemen, J. G., Hendriks, E. R., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01602-8
The molecular pathological basis and potential clinical applications of ‘zero‐budding’ status in stage II colorectal cancer
Liu, Y.-N., Wang, B., & Xu, Q. (2026) · The Journal of Pathology Clinical Research · doi:10.1002/2056-4538.70120
An Explainable Multimodal Deep‐Learning Model Using Histopathological Image and Clinical Information for Prognosis Prediction in Colorectal Cancer: A Multi‐Center Cohort Study
Jiang, Z., Shi, X., Su, C., Ma, Y., Li, R., Chen, M., Cui, J., Hawkins, N., Ward, R., Bai, X., et al. (2026) · Advanced Science · doi:10.1002/advs.78417

Mosaic Study: Actualization of Overall Survival (Os) with 10 Years Follow Up and Evaluation of Braf. By Gercor and Mosaic Investigators
André, T., de Gramont, A., Chibaudel, B., Tijeras‐Raballand, A., Duval, A., Hickish, T., Tabernero, J. M., Laethem, J. V., Banzi, M. C., Maartense, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu333.5 · Cited by 3
Self-citation
Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.
Fléjou, J., André, T., Chibaudel, B., Scriva, A., Hickish, T., Tabernero, J. M., Laethem, J. V., Banzi, M. C., Maartense, E., Shani, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3524 · Cited by 23
Self-citation
Prognostic Effect ofBRAFandKRASMutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab
Taı̈eb, J., Zaanan, A., Malicot, K. L., Julié, C., Blons, H., Mineur, L., Bennouna, J., Tabernero, J. M., Mini, E., Folprecht, G., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5225 · Cited by 164
Self-citation
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
André, T., Boni, C., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Bonetti, A. V., Clingan, P. R., Bridgewater, J. A., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,276
Self-citation
Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy
Sinicrope, F. A., Mahoney, M. R., Smyrk, T. C., Thibodeau, S. N., Warren, R. S., Bertagnolli, M. M., Nelson, G. D., Goldberg, R. M., Sargent, D. J., & Alberts, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9591 · Cited by 285

See all

Authors: André, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., Banzi, M., Maartense, E., Shmueli, E., Carlsson, G. U., Scheithauer, W., Papamichael, D., Möehler, M., Landolfi, S., Demetter, P., Colote, S., Tournigand, C., Louvet, C., Duval, A., Fléjou, J.-F., & de Gramont, A.
Affiliations: Inserm (FR)
Thierry André and Jean-François Fléjou, Hôpital St Antoine; Thierry André and Jean-François Fléjou, University Pierre et Marie Curie Paris VI; Thierry André, Benoist Chibaudel, Annemilaï Tijeras-Raballand, Soudhir Colote, and Aimery de Gramont, Groupe Coopérateur Multdisciplinaire en Ocologie (GERCOR) Oncology Multidisciplinary Group and GERCOR-Innovative Research Consortium; Christophe Louvet, Institut Mutualiste Montsouris; Alex Duval, L'Institut National de la Santé et de la Recherche Médicale UMRS...
ORCID: André, Thierry
Chibaudel, Benoist
Hickish, Tamas
Tabernero, Josep
Banzi, Maria
Shmueli, Einat
Papamichael, Demetris
Landolfi, Stefania
Demetter, Pieter
Tournigand, Christophe
Louvet, Christophe
Duval, Alex
Fléjou, Jean-François
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-12-10
Volume: 33
Issue: 35
Pages: 4176-4187
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2015.63.4238
OpenAlex: W1960485012
Cited by: 683
References: 32
Citations by year: 2026: 43 · 2025: 56 · 2024: 75 · 2023: 65 · 2022: 74 · 2021: 92 · 2020: 97 · 2019: 47 · 2018: 59 · 2017: 41 · 2016: 32
FWCI: 19.22
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Funders: European Society for Medical Oncology
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: colon cancer, adjuvant chemotherapy, oxaliplatin, FOLFOX4, 5-fluorouracil, leucovorin, BRAF mutation, mismatch repair deficiency, overall survival, disease-free survival, prognostic factors, stage II colon cancer, stage III colon cancer, mosaic studies, long-term follow-up, microsatellite instability, mismatch repair proteins
MeSH terms: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Colonic Neoplasms, Female, Fluorouracil, Follow-Up Studies, Humans, Infusions, Intravenous, Injections, Intravenous, Male, Middle Aged, Mutation, Neoplasm Staging, Organoplatinum Compounds, Prognosis, Valine, Odds Ratio, Treatment Outcome, Chemotherapy, Adjuvant, Disease-Free Survival, Glutamic Acid, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate, DNA Mismatch Repair

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks